Vaginal dryness and genitourinary syndrome of menopause

Vaginal dryness is usually described as an inconvenience, which is part of why it goes untreated for years. It is more accurate to describe it as one progressive condition affecting the vulva, vagina, urethra, and bladder together, now called genitourinary syndrome of menopause. Unlike hot flashes, it does not fade with time; left alone it slowly worsens. It is also one of the most treatable problems in menopausal medicine, and the treatments are effective, inexpensive, and safer than their labeling has historically suggested.

One condition, not a list of separate complaints

The tissues of the vulva, vagina, urethra, and bladder trigone all carry estrogen receptors and all respond to estrogen loss in the same way. The vaginal wall thins and loses elasticity, blood flow falls, natural lubrication declines, and the pH rises, which shifts the resident bacteria away from lactobacilli. The vulvar skin becomes thinner and more fragile, and over years the labia minora may flatten and the vaginal opening narrow. The urethra and bladder neck are affected at the same time, which is why urinary urgency, frequency, discomfort on voiding, and recurrent infection belong in this discussion rather than being sent off as a separate problem.

Patients rarely present with all of it at once. More often it is one thread: sex has become uncomfortable, or there is a persistent raw feeling in leggings, or a third urinary tract infection in a year, or bleeding after intercourse that is alarming and needs evaluating. Recognizing these as one condition matters because one treatment addresses the whole of it, whereas treating each complaint separately tends to produce a cupboard full of antibiotics and creams that do not fix the underlying tissue change.

Why it does not settle down on its own

Hot flashes eventually burn out for most women; the hypothalamus adapts. The genitourinary tissues do not adapt, because the change is structural rather than a matter of thermoregulatory signaling. Without estrogen the epithelium stays thin, collagen continues to remodel, and the tissue becomes progressively less able to stretch. This is why waiting does not help and why the women who present ten years after menopause typically have a harder problem to treat than those who present at two years.

There is also a behavioral spiral that tends to set in. Sex hurts, so it happens less often or is avoided; the pelvic floor learns to brace in anticipation; the introitus becomes less accommodating; the next attempt hurts more. By the time someone seeks help, tissue atrophy and pelvic floor hypertonicity are frequently both present, and the second one does not respond to estrogen. That is one of the main reasons treatment sometimes needs more than a prescription.

Starting without hormones

Moisturizers and lubricants are different products and confusing them is the most common reason women conclude that over-the-counter treatment does not work. A vaginal moisturizer is used regularly, typically two or three times a week regardless of sexual activity, and works by rehydrating the tissue over time; hyaluronic acid and polycarbophil-based products are the ones with reasonable data behind them. A lubricant is used at the time of sex and does nothing between times. Many women need both, and using only a lubricant while expecting the tissue to improve is a setup for disappointment.

Product choice matters more than it should. Highly concentrated glycerin-based and warming products can irritate thin tissue, and very high osmolality formulations may damage the epithelium. Silicone lubricants last longer and suit dry tissue well, though they should not be used with silicone devices. Alongside this we generally advise abandoning soaps, washes, wipes, and douches on the vulva, which are a frequent and entirely avoidable source of irritation, and using a bland emollient externally instead.

Vaginal estrogen and the warning on the box

Low-dose vaginal estrogen is the most effective treatment for genitourinary syndrome of menopause and it is the reference point against which everything else is judged. It comes as a cream, a tablet or softgel insert, or a slow-release ring, and it works by restoring the epithelium rather than coating it. Typical dosing is nightly for two weeks and then twice weekly indefinitely; benefit is usually apparent within a few weeks and full effect takes around twelve. It needs to be continued, because the tissue returns to its untreated state when it is stopped.

For years these products carried the same boxed warning as systemic hormone therapy, describing risks of endometrial cancer, cardiovascular disease, and dementia that were derived from trials of systemic estrogen in older women. Professional bodies including the Menopause Society and ACOG argued for a long time that this warning was not supported by evidence for low-dose vaginal preparations, because systemic absorption at these doses is minimal and serum estradiol generally stays within the postmenopausal range. The FDA has since moved to remove the boxed warning from these products. If your pharmacy leaflet still carries it, that is a labeling lag, not new information.

Vaginal DHEA and oral ospemifene

Prasterone, a vaginal DHEA insert used nightly, is converted locally into estrogen and androgen within the vaginal cells and is an FDA-approved alternative with good evidence for painful intercourse. Some women prefer it precisely because it is not labeled as an estrogen. Ospemifene is an oral selective estrogen receptor modulator taken daily, approved for moderate to severe dyspareunia and dryness, and useful when someone wants to avoid inserting anything; it can cause hot flashes and carries a clotting risk, so it suits some women and not others.

Nobody should be on their fourth course of antibiotics for urinary infections without anyone having examined the tissue that is causing them.

If you have had breast cancer

This is the situation that requires the most care and the most honesty. Systemic hormone therapy is contraindicated after breast cancer. Local vaginal estrogen is a separate question, and the current position of the major oncology and menopause bodies is that non-hormonal measures should be tried first, and that if they fail, low-dose vaginal estrogen may be considered in selected women after discussion with the treating oncologist. The available data, which are observational rather than randomized, have not shown an increase in recurrence, but observational data cannot settle the question definitively and we will not tell you that they have.

The nuance that matters is which endocrine therapy you are on. Aromatase inhibitors work by driving systemic estrogen close to zero, so even small rises are of theoretical concern, and caution is greater in that group; with tamoxifen the concern is lower. Vaginal DHEA and ospemifene are sometimes proposed as alternatives, though the evidence base in survivors is likewise limited. In practice this is a shared decision between you, us, and your oncologist, weighed against a symptom burden that is often severe and frequently under-treated in exactly this group.

Bladder, pelvic floor, and sex

Recurrent urinary tract infection after menopause is one of the clearest wins in this area. Randomized evidence supports vaginal estrogen for reducing recurrence, and urology guidelines recommend it for postmenopausal women with recurrent infections. The mechanism is straightforward: restoring the vaginal epithelium restores lactobacilli and lowers pH, which makes colonization by urinary pathogens less likely. Because urology practices within our group, women whose main problem is urgency, incontinence, or repeated infection can be assessed for both the gynecologic and urologic components without being referred out and starting again.

Where sex has been painful for a long time, estrogen alone often does not finish the job. Pelvic floor physical therapy addresses the protective muscle guarding that develops around painful intercourse, and graduated dilator use restores tolerance of penetration where the introitus has narrowed. Some couples benefit from formal sex therapy alongside the physical treatment, because months or years of pain leave their mark on desire and on the relationship. We would rather set that expectation at the start than have you conclude after six weeks of cream that nothing works.